Publication: Optimized dosing regimen of hydroxychloroquine for treatment of coronavirus disease 2019 using Monte Carlo simulation
Issued Date
2021-01-01
Resource Type
ISSN
25868470
25868195
25868195
Other identifier(s)
2-s2.0-85119204336
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmaceutical Sciences Asia. Vol.48, No.5 (2021), 425-431
Suggested Citation
Sumit Leevanichchakhul, Pitchaya Dilokpattanamongkol, Taniya Paiboonvong, Suwida Tangtrakultham, Supatat Chumnumwat, Sasisopin Kiertiburanakul, Preecha Montakantikul Optimized dosing regimen of hydroxychloroquine for treatment of coronavirus disease 2019 using Monte Carlo simulation. Pharmaceutical Sciences Asia. Vol.48, No.5 (2021), 425-431. doi:10.29090/psa.2021.05.21.002 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78570
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Optimized dosing regimen of hydroxychloroquine for treatment of coronavirus disease 2019 using Monte Carlo simulation
Abstract
Optimized dosage regimens of hydroxychloroquine (HCQ) in coronavirus disease 2019 (COVID-19) are currently unknown. We aimed to determine regimens that rapidly achieved the pharmacokinetic-pharmacodynamic (PKPD) target for virological clearance in COVID-19 patients. Plasma HCQ concentration was simulated using a non-steady state, 2-compartment linear model. The plasma trough concentration (Ctrough) > 0.7 mg/L was used as the PKPD target. The loading dose of 800 mg three times daily and 1,200 mg twice daily achieved the target on the first day with the probability of target attainment (PTA) 97.53% and 82.63%, respectively. Maintenance dose of 200 mg three times daily and 400 mg twice daily provided PTA > 80% from day 3 through day 10 after the initiation of HCQ therapy. All proposed regimens had the PTA < 1% to achieve toxic level of 4 mg/L. The optimal dose regimens for early viral clearance in COVID-19 patients were HCQ 800 mg three times daily on the first day followed by 200 mg three times daily for 9 days, and HCQ 1,200 mg twice daily on the first day followed by 400 mg twice daily for 9 days. Further clinical study is needed to ensure clinical efficacy and safety of these regimens.